Drug Trial Radar · NCT05365581
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
398
Planned (sponsor's estimate)
Start
Jun 7, 2022
Primary completion
May 31, 2028
Study completion May 31, 2028
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- May 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a protein on a type of immune cell called a T-cell. This "tells" the immune system to attack the tumor. ASP2138 is a potential treatment for people with stomach cancer, gastroesophageal junction cancer (GEJ cancer) or pancreatic cancer. GEJ is where the tube that carries food (esophagus) joins the stomach. Before ASP2138 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body. In this study, ASP2138 will either be given by itself, or given together with standard treatments for gastric, GEJ and pancreatic cancer. Pembrolizumab and mFOLFOX6, and ramucirumab and paclitaxel are standard treatments for gastric and GEJ cancer. mFOLFIRINOX is a standard treatment for pancreatic cancer. This information will help find a suitable dose of ASP2138 given by itself and together with the standard cancer treatments and to check for potential medical problems from the treatments. The main aims of the study are: * To check the safety of ASP2138 and how well people can tolerate medical problems during the study. * To find a suitable dose of ASP2138 to be used later in the study. * These are done for ASP2138 given by itself and when given together with the standard cancer treatments. Adults 18 years or older with stomach cancer, GEJ cancer, or pancreatic cancer can take part. Their cancer is locally advanced unresectable or metastatic. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. There should also be the CLDN18.2 marker in a tumor sample. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers, have specific infections, have a condition such as hemophagocytic lymphohistiocytosis (HLH) which is when the body over-reacts to a "trigger" such as infection, or have a specific heart condition ("New York Heart Association Class III or IV"). Phase 1: Lower to higher doses of ASP2138 * ASP2138 is either given through a vein (intravenous infusion) or just under the skin (subcutaneous injection). * Different small groups are given lower to higher doses of ASAP2138. * ASP2138 is either given by itself, or given with 1 of 3 standard treatments: * Pembrolizumab and mFOLFOX6 (first treatment for gastric GEJ cancer) * Ramacirumab and paclitaxel (Second treatment for gastric or GEJ cancer) * ASP2138 with mFOLFIRINOX (first treatment for pancreatic cancer) Phase 1b: doses of ASP2138 worked out from Phase 1 * ASP2138 is either given through a vein or just under the skin. This depends on the findings from Phase 1. * People with gastric cancer, GEJ cancer or pancreatic cancer are given doses of ASP2138, worked out from Phase 1. * This includes doses of ASP2138 given by itself and ASP2138 given with the standard cancer treatments. * The standard cancer treatments given depends on the type of cancer they have. End of treatment visit: This is 7 days after final dose of study treatment or if the study doctor decides to stop the person's treatment. People who have locally advanced unresectable pancreatic cancer will not receive ASP2138 by itself.
Conditions
- Gastric Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Pancreatic Adenocarcinoma
Interventions
ASP2138Drug
Intravenously or Subcutaneously
PembrolizumabDrug
Intravenously
OxaliplatinDrug
Intravenously
LeucovorinDrug
Intravenously
FluorouracilDrug
Intravenously
RamucirumabDrug
Intravenously
PaclitaxelDrug
Intravenously
IrinotecanDrug
Intravenously
CapecitabineDrug
Oral Administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Dose Escalation)Time frame: Up to 28 days
- Number of participants with Adverse Events (AEs)Time frame: Up to 27 months
- Number of participants with serious AEs (SAEs)Time frame: Up to 27 months
- Number of participants with laboratory value abnormalitiesTime frame: Up to 25 months
- Number of participants with vital sign abnormalitiesTime frame: Up to 27 months
- Number of participants with electrocardiogram (ECG) abnormalitiesTime frame: Up to 24 months
- Number of participants with physical exam abnormalitiesTime frame: Up to 25 months
- Number of participants at each grade of the Eastern Cooperative Oncology Group (ECOG) performance statusTime frame: Up to 25 months
Locations
46 sites in 8 countries. Site status is shown where the registry gives one.
University of California Irvine Medical Center
Orange, California · Recruiting
UCLA Dept of Medicine - Hematology/Oncology, Santa Monica
Santa Monica, California · Withdrawn
Northwestern University
Chicago, Illinois · Recruiting
University of Kansas Cancer Center
Westwood, Kansas · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Completed
NYU Langone Medical Center - NYU Medical Oncology Associates
New York, New York · Recruiting
Columbia University
New York, New York · Completed
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke Children's Hospital and Health Center
Durham, North Carolina · Recruiting
Wake Forest University Baptist Health
Winston-Salem, North Carolina · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Virginia Mason Medical Center
Seattle, Washington · Recruiting
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Site FR33003
Lyon, France · Recruiting
Site FR33004
Marseille, France · Recruiting
Site FR33006
Poitiers, France · Recruiting
Site FR33001
Saint-Herblain, France · Recruiting
Site FR33002
Toulouse, France · Recruiting
Site FR33005
Vaillant, Villejuif, France · Recruiting
Site IT39004
Milan, Italy · Recruiting
Site IT39001
Milan, Italy · Recruiting
Site IT39005
Rozzano, Italy · Recruiting
Site IT39003
Verona, Italy · Recruiting
Aichi Cancer Center
Nagoya, Aichi-ken, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa, Chiba, Japan · Recruiting
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan · Recruiting
Kindai University Hospital
Sakai, Osaka, Japan · Recruiting
The University of Osaka Hospital
Suita, Osaka, Japan · Recruiting
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan · Completed
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Koto-ku, Tokyo, Japan · Recruiting
PanOncology Trials
San Juan, Puerto Rico · Recruiting
Site KR82004
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Site KR82001
Guro-gu, Seoul, South Korea · Recruiting
Site KR82002
Jongno-gu, Seoul, South Korea · Recruiting
Site KR82003
Seocho-gu, Seoul, South Korea · Recruiting
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.